Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
TARA
Stock Latest News
Ratings
Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC Amidst BCG Shortages
5d ago
TARA
Premium
Ratings
Protara Therapeutics’ TARA-002: Promising Phase 2 Results Bolster Buy Rating Amidst FDA Uncertainty
10d ago
TARA
Premium
Ratings
Promising Phase 2 Results and Strategic Planning Justify Buy Rating for TARA-002
10d ago
TARA
Premium
Company Announcements
Protara Therapeutics Announces Promising Phase 2 Trial Results
10d ago
8K
TARA
Premium
The Fly
Protara announces results from Phase 2 STARBORN-1 trial of TARA-002
10d ago
TARA
Premium
Ratings
Protara Therapeutics: Promising Developments and Strategic Positioning Drive Buy Rating
12d ago
TARA
Premium
Company Announcements
Protara Therapeutics Reports Q3 2025 Financial Results
18d ago
TARA
Premium
Ratings
Protara Therapeutics: Strategic Developments and Upcoming Milestones Drive Buy Rating
19d ago
TARA
Premium
Ratings
Buy Rating for Protara Therapeutics: Promising Developments with TARA-002 in Lymphatic Malformations
19d ago
TARA
Premium
Ratings
Protara Therapeutics: Promising Pipeline and Strong Financial Position Reinforce Buy Rating
19d ago
TARA
Premium
The Fly
Protara Therapeutics reports Q3 EPS (31c), consensus (38c)
19d ago
TARA
Premium
The Fly
Protara Therapeutics sees cash runway into mid-2027
19d ago
TARA
Premium
Pre-Earnings
Protara Therapeutics, Inc. (TARA) Q3 Earnings Cheat Sheet
1M ago
TARA
Premium
Company Announcements
Protara Therapeutics Advances Phase 2 Study for Bladder Cancer Treatment
1M ago
TARA
Premium
Company Announcements
Protara Therapeutics’ Choline Chloride Study: A Potential Game-Changer for Intestinal Failure Treatment
1M ago
TARA
Premium
Company Announcements
Protara Therapeutics’ TARA-002 Study: A Potential Game-Changer for Lymphatic Malformations
1M ago
TARA
Premium
Ratings
Optimistic Outlook for Protara Therapeutics: Buy Rating Driven by Promising TARA-002 Developments and Strategic Opportunities
1M ago
TARA
Premium
Ratings
Promising Developments in Protara Therapeutics’ Lymphatic Malformation Program Support Buy Rating
2M ago
TARA
Premium
Ratings
Protara Therapeutics: Buy Rating Affirmed Amid Promising Developments in Bladder Cancer and Beyond
2M ago
TARA
Premium
Stock Analysis & Ideas
Analysts Predict Up to 840% Jump for These 2 ‘Strong Buy’ Penny Stocks
2M ago
TARA
TKNO
Premium
The Fly
Citizens JMP healthcare analysts hold an analyst/industry conference call
2M ago
JNJ
CGON
Premium
The Fly
Citizens JMP healthcare analysts hold an analyst/industry conference call
3M ago
JNJ
CGON
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
